Profile
Dennis Hom currently works at ProQR Therapeutics NV, as Chief Financial Officer from 2025.
Mr. Hom also formerly worked at Amgen, Inc., as Executive Director-Corporate Development from 2011 to 2012, Achaogen, Inc., as Vice President-Finance & Corporate Development from 2013 to 2014, and Sagimet Biosciences, Inc., as CFO & Head-Corporate Development from 2017 to 2023.
Mr. Hom received his undergraduate degree from Massachusetts Institute of Technology.
Dennis Hom active positions
| Companies | Position | Start |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Director of Finance/CFO | 2025-04-13 |
Former positions of Dennis Hom
| Companies | Position | End |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Director of Finance/CFO | 2023-07-31 |
| ACHAOGEN | Director of Finance/CFO | 2014-03-30 |
| AMGEN INC. | Corporate Officer/Principal | 2011-12-31 |
Training of Dennis Hom
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Sagimet Biosciences, Inc.
Sagimet Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel therapeutics for the treatment of infectious diseases | Health Technology |
ProQR Therapeutics NV
ProQR Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders | Health Technology |
- Stock Market
- Insiders
- Dennis Hom
















